Objective To investigate the clinical value of tumor marker combined with cytokeratin 18 and 19 in the diagnosis of malignant tumors .Methods 264 patients with malignant tumor were selected as the observation group.During the same period,136 patients with benign tumor were selected as the control group .The tumor markers, cytokeratin 18 (CK18) and cytokeratin 19 (CK19) levels were compared between the two groups ,and the positive detection rate of tumor markers combined with CK 18 and CK19 were analyzed .Results The serum CK18 and CK19 levels of the observation group were (25.48 ±75.14) U/L,(18.67 ±64.85)U/L,respectively,which were signifi-cantly higher than those of the control group [(0.56 ±1.52)U/L,(0.76 ±0.43)U/L],the differences were statisti-cally significant (t=17.38,15.75,all P<0.05).The serum levels of CEA,CA125,CA50,CA19-9 and TSGF of the observation group were (21.24 ±30.16) μg/L,(69.85 ±112.75) mU/L,(47.32 ±121.81) mU/L,(41.87 ± 20.65) mU/L,(91.64 ±43.84) mU/L,respectively,which were significantly higher than those of the control group [(1.27 ±0.85) ng/mL,(15.82 ±3.87) mU/L,(12.85 ±31.65) mU/L,(6.89 ±4.85) mU/L,(38.35 ± 8.01) mU/L],the differences were statistically significant (t=15.73,16.89,14.86,17.79,16.73,all P<0.05).The positive detection rates of CK18 and CK19 for gastric cancer (66.67％) and lung cancer (77.14％) were signif-icantly higher than tumor markers ,and the differences were statistically significant (χ2 =5.67,6.78,all P<0.05). The positive detection rate of tumor markers combined with CK 18 and CK19 for malignant tumors ( 75.00％) was significantly higher than CK18 and CK19 joint detection (65.91％),tumor markers (46.97％),the differences were statistically significant (χ2 =6.78,7.12,all P<0.05).Conclusion Tumor markers combined with CK18 and CK19 detection is helpful to improve the detection rate of malignant tumors and provide effective basis for following treatment.

OBJECTIVETo probe the significance of specific IgG4 in sera of patients with cerebral cysticercosis for diagnosis and therapeutic evaluation.

METHODSSpecific IgG4 in sera of patients with cerebral cysticercosis was assessed using colloidal gold-labeled mouse-anti-human IgG4 McAb as probe. The results were compared with the CT image manifestation.

RESULTSThe specific IgG4 positive rate in sera of patients with cerebral cysticercosis was 97.8%, whereas sera from patients with other kinds of parasitosis or central nerve system disease and the control group were all negative, except for a weak cross-reaction of sera from patients with hepatic echinococoosis. The determination of specific IgG4 in sera of patients with cerebral cysticercosis during different times of treatment showed that along with an increase in treatment time and improvement of clinical symptoms, specific IgG4 level gradually decreased. The positive rate and intensity of specific IgG4 in sera from patients with cerebral cysticercosis were consistent with the number of cysticercus parasites in the brain and pathologic changes, such as survival, disintegration, death and calcification. Survival of cysticercus in the brain was objectively evaluated using this technique.

CONCLUSIONSThe determination of specific IgG4 in sera is a practical method for diagnosis and therapeutic evaluation of cerebral cysticercosis.

Animals ; Antibodies, Monoclonal ; immunology ; Antibody Specificity ; Humans ; Immunoglobulin G ; blood ; immunology ; Mice ; Mice, Inbred BALB C ; Neurocysticercosis ; blood ; diagnosis ; therapy ; Predictive Value of Tests ; Tomography, X-Ray Computed